Zentalis Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018
Cash & Equivalents	30.72	45.7	62.58	56.27	67.49	25.15
Short-Term Investments	454.88	394.3	280.17	283.55	0	0
Cash & Cash Equivalents	485.6	440	342.76	339.83	67.49	25.15
Cash Growth	10.36%	28.37%	0.86%	403.53%	168.30%	-
Receivables	0	0	0	0.42	0.14	0.92
Other Current Assets	11.12	11.94	8.01	4.86	1.26	0.61
Total Current Assets	496.72	451.93	350.77	345.1	68.89	26.68
Property, Plant & Equipment	41.74	50.08	52.84	3.62	2.84	0.26
Long-Term Investments	0	21.21	37.5	0	0	0
Goodwill and Intangibles	3.74	3.74	3.74	3.74	3.74	3.74
Other Long-Term Assets	9.5	12.35	9.67	13.1	12.02	10.33
Total Long-Term Assets	54.97	87.38	103.74	20.45	18.59	14.32
Total Assets	551.69	539.31	454.51	365.56	87.48	41
Accounts Payable	14.93	11.25	11.59	8.66	4.29	3.43
Deferred Revenue	0	0	0	0	0	0.22
Other Current Liabilities	54.44	45.4	32.35	19.94	10.61	2.55
Total Current Liabilities	69.37	56.65	43.94	28.6	14.9	6.21
Long-Term Debt	43.15	45.17	44.46	1.1	0	0
Other Long-Term Liabilities	1.78	3.47	1.62	2.48	4.16	2.48
Total Long-Term Liabilities	44.93	48.64	46.08	3.58	4.16	2.48
Total Liabilities	114.3	105.29	90.03	32.18	19.06	8.69
Total Debt	43.15	45.17	44.46	1.1	0	0
Debt Growth	-4.46%	1.59%	3952.78%	-	-	-
Retained Earnings	-888.56	-596.37	-359.56	-200.83	-82.99	-37.33
Comprehensive Income	2.19	-1.35	-0.13	0.04	0	0
Shareholders' Equity	437.28	433.8	363.95	308.58	-80.11	24.77
Net Cash / Debt	442.45	394.83	298.3	338.73	67.49	25.15
Net Cash / Debt Growth	12.06%	32.36%	-11.94%	401.90%	168.30%	-
Net Cash Per Share	6.76	7.47	6.99	12.05	12.06	4.50
Working Capital	427.35	395.29	306.83	316.5	53.99	20.47
Book Value Per Share	6.68	8.21	8.53	10.98	-14.31	4.43

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).